GlassScriptPhysician profile
Joseph Aloise
NPI 1275528564
$660.28
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $324 · 2021: $17.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $293.12 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $60.40 | 2019 | |
| Glaxosmithkline, LLC. | $58.02 | 2019-2020 | |
| Eisai INC. | $47.01 | 2020 | |
| Lilly USA, LLC | $41.68 | 2020 | |
| Amgen INC. | $41.52 | 2019-2020 | |
| Indivior INC. | $25.82 | 2019 | |
| Amarin Pharma, INC. | $23.69 | 2019 | |
| Gilead Sciences, INC. | $17.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.60 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.98 | 2019 | |
| Merck Sharp & Dohme LLC | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Aloise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.